Search results

Here you have the SLE patients vs controls from the actual pre printed study. I cannot see a pattern here for SLE but it is quite interesting anyway: And here you can see APECED to controls. Of course APECED is know serious disease and here is a clear pattern:

This is also inline with the recent work and patent application from Fluge and Mella as discussed in another post. The application actually mentions Daratumumab as a possible therapeutic agent: Patent: Method for the treatment of CFS using an inhibitory or cytotoxic agent against plasma cells...

Hi all. Thanks for the positive feedback on this. This technology has already been used in one Covid-19 study and has been featured as I said in Nature, NYT and Guardian. You might have come across those articles from somewhere else but I post here links to the actual study and news as a...

I personally believe that ME/CFS is antibody driven and I therefore think this breakthrough technology could tell us alot about at least a subset of patients. Here you can identify antibodies to extracelluar proteins (non tissue degenerating) which relates to us as patients since there is no...

See also: Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases? CD38 is a type II glycoprotein highly expressed on plasmablasts, short-lived and long-lived plasma cells, but weakly expressed on other lymphoid cells, myeloid cells and non-hematopoietic cells. This...

Summary Daratumumab, a human monoclonal antibody that targets CD38, depletes plasma cells and is approved for the treatment of multiple myeloma. Long-lived plasma cells are implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies, but they are...